Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2020

01-06-2020 | Gastrostomy | Peritoneal Surface Malignancy

The Chicago Consensus on Peritoneal Surface Malignancies: Palliative Care Considerations

Author: Chicago Consensus Working Group

Published in: Annals of Surgical Oncology | Issue 6/2020

Login to get access

Abstract

The Chicago Consensus Working Group provides multidisciplinary recommendations for palliative care specifically related to peritoneal surface malignancies. These guidelines are developed with input from leading experts including surgical oncologists, medical oncologists, gynecologic oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
Literature
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
Clark K, Lam L, Currow D. Reducing gastric secretions—a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction? Support Care Cancer. 2009;17(12):1463–68.PubMed
12.
De Conno F, Caraceni A, Zecca E, Spoldi E, Ventafridda V. Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manage. 1991;6(8):484–86.PubMed
13.
Peng X, Wang P, Li S, Zhang G, Hu S. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. World J Surg Oncol. 2015;13:50.PubMedPubMedCentral
14.
Mittal DL, Mittal A, Brosnan EA, Landman WJ. Nonopioid pharmacological management of malignant bowel obstruction: a New Zealand-wide survey. J Palliat Med. 2014;17(11):1249–55.PubMed
15.
16.
Minoura T, Takeuchi M, Morita T, Kawakami K. Practice patterns of medications for patients with malignant bowel obstruction using a nationwide claims database and the association between treatment outcomes and concomitant use of H2-blockers/proton pump inhibitors and corticosteroids with octreotide. J Pain Symptom Manage. 2018;55(2):413–19.PubMed
17.
Currow DC, Quinn S, Agar M, et al. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction. J Pain Symptom Manage. 2015;49(5):814–21.PubMed
18.
Khoo D, Hall E, Motson R, Riley J, Deaman K, Waxman J. Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer. 1994;30A(1):28–30.PubMed
19.
Hisanaga T, Shinjo T, Morita T, et al. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol. 2010;40(8):739–45.PubMed
20.
Shima Y, Ohtsu A, Shirao K, Sasaki Y. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction. Jpn J Clin Oncol. 2008;38(5):354–59.PubMed
21.
Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage. 2000;19(1):23–32.PubMed
22.
Mercadente S, Ripamonti C, Casuccio A, Zecca E, Groff L. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer. 2000;8:188–91.
23.
Matulonis UA, Seiden MV, Roche M, et al. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage. 2005;30(6):563–69.PubMed
24.
Herman LL, Hoskins WJ, Shike M. Percutaneous endoscopic gastrostomy for decompression of the stomach and small bowel. Gastrointest Endosc. 1992;38(3):314–18.PubMed
25.
Pothuri B, Montemarano M, Gerardi M, et al. Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol. 2005;96(2):330–34.PubMed
26.
Kawata N, Kakushima N, Tanaka M, et al. Percutaneous endoscopic gastrostomy for decompression of malignant bowel obstruction. Dig Endosc. 2014;26(2):208–13.PubMed
27.
Issaka RB, Shapiro DM, Parikh ND, et al. Palliative venting percutaneous endoscopic gastrostomy tube is safe and effective in patients with malignant obstruction. Surg Endosc. 2014;28(5):1668–73.PubMed
28.
Vashi PG, Dahlk S, Vashi RP, Gupta D. Percutaneous endoscopic gastrostomy tube occlusion in malignant peritoneal carcinomatosis-induced bowel obstruction. Eur J Gastroenterol Hepatol. 2011;23(11):1069–73.PubMed
29.
Dittrich A, Schubert B, Kramer M, et al. Benefits and risks of a percutaneous endoscopic gastrostomy (PEG) for decompression in patients with malignant gastrointestinal obstruction. Support Care Cancer. 2017;25(9):2849–56.PubMed
30.
Zucchi E, Fornasarig M, Martella L, et al. Decompressive percutaneous endoscopic gastrostomy in advanced cancer patients with small-bowel obstruction is feasible and effective: a large prospective study. Support Care Cancer. 2016;24(7):2877–82.PubMed
31.
Pinard KA, Goring TN, Egan BC, Koo DJ. Drainage percutaneous endoscopic gastrostomy for malignant bowel obstruction in gastrointestinal cancers: prognosis and implications for timing of palliative intervention. J Palliat Med. 2017;20(7):774–78.PubMed
32.
Shaw C, Bassett RL, Fox PS, et al. Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites. Ann Surg Oncol. 2013;20(2):497–505.PubMed
33.
Cauley CE, Panizales MT, Reznor G, et al. Outcomes after emergency abdominal surgery in patients with advanced cancer: opportunities to reduce complications and improve palliative care. J Trauma Acute Care Surg. 2015;79(3):399–406.PubMedPubMedCentral
34.
Pameijer CR, Mahvi DM, Stewart JA, Weber SM. Bowel obstruction in patients with metastatic cancer: does intervention influence outcome? Int J Gastrointest Cancer. 2005;35(2):127–133.PubMed
35.
Lambert LA, Hendrix RJ. Palliative management of advanced peritoneal carcinomatosis. Surg Oncol Clin N Am. 2018;27(3):585-602.PubMed
36.
Hébuterne X, Lemarié E, Michallet M, de Montreuil CB, Schneider SM, Goldwasser F. Prevalence of malnutrition and current use of nutrition support in patients with cancer. JPEN J Parenter Enteral Nutr. 2014;38(2):196-204.PubMed
37.
Vashi PG, Gupta D, Lammersfeld C, et al. The relationship between baseline nutritional status with subsequent parenteral nutrition and clinical outcomes in cancer patients undergoing hyperthermic intraperitoneal chemotherapy. Nutr J. 2013;12:118.PubMedPubMedCentral
38.
Kwag SJ, Kim JG, Kang WK, Lee JK, Oh ST. The nutritional risk is a independent factor for postoperative morbidity in surgery for colorectal cancer. Ann Surg Treat Res. 2014;86(4):206-11.PubMedPubMedCentral
39.
Harrison LE, Brennan MF. The role of total parenteral nutrition in the patient with cancer. Curr Probl Surgery. 1995;32(10):833-917.
40.
Koretz RL, Lipman TO, Klein S; American Gastroenterological Association AGA technical review on parenteral nutrition. Gastroenterology. 2001;121(4):970-1001.PubMed
41.
Abu-Rustum NR, Barakat RR, Venkatraman E, Spriggs D. Chemotherapy and total parenteral nutrition for advanced ovarian cancer with bowel obstruction. Gynecol Oncol. 1997;64:493-95.PubMed
42.
Brard L, Weitzen S, Strubel-Lagan SL, et al. The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. Gynecol Oncol. 2006;103(1):176-180.PubMed
43.
Diver E, O’Connor O, Garrett L, et al. Modest benefit of total parenteral nutrition and chemotherapy after venting gastrostomy tube placement. Gynecol Oncol. 2013;129(2):332-35.PubMed
44.
Rath KS, Loseth D, Muscarella P, et al. Outcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer. Gynecol Oncol. 2013;129(1):103-106.PubMedPubMedCentral
45.
Fan BG. Parenteral nutrition prolongs the survival of patients associated with malignant gastrointestinal obstruction. JPEN J Parenter Enteral Nutr. 2007;31(6):508-10.PubMed
46.
Chermesh I, Mashiach T, Amit A, et al. Home parenteral nutrition (HTPN) for incurable patients with cancer with gastrointestinal obstruction: do the benefits outweigh the risks? Med Oncol. 2011;28(1):83-88.PubMed
47.
Cozzaglio L, Balzola F, Cosentino F, et al. Outcome of cancer patients receiving home parenteral nutrition. Italian Society of Parenteral and Enteral Nutrition (S.I.N.P.E.). JPEN J Parenter Enteral Nutr. 1997;21(6):339-42.PubMed
48.
Pasanisi F, Orban A, Scalfi L, et al. Predictors of survival in terminal-cancer patients with irreversible bowel obstruction receiving home parenteral nutrition. Nutrition. 2001;17(7-8):581-84.PubMed
49.
Soo I, Gramlich L. Use of parenteral nutrition in patients with advanced cancer. Appl Physiol Nutr Metab. 2008;33(1):102-106.PubMed
50.
Aria Guerra E, Cortés-Salgado A, Mateo-Lobo R, et al. Role of parenteral nutrition in oncologic patients with intestinal occlusion and peritoneal carcinomatosis. Nutr Hosp. 2015;32(3):1222-27.PubMed
51.
Chouhan J, Gupta R, Ensor J, et al. Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. Cancer Med. 2016;5(2):239-47.PubMed
52.
Naghibi M, Smith TR, Elia M. A systematic review with meta-analysis of survival, quality of life and cost-effectiveness of home parenteral nutrition in patients with inoperable malignant bowel obstruction. Clin Nutr. 2015;34(5):825-37.PubMed
53.
Sowerbutts AM, Lal S, Sremanakova J, et al. Home parenteral nutrition for people with inoperable malignant bowel obstruction. Cochrane Database Syst Rev. 2018;8:12.
54.
Bozzetti F, Arends J, Lundholm K, Micklewright A, Zurcher G, Muscaritoli M; ESPEN. ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology. Clin Nutr. 2009;28(4):445-54.PubMed
55.
Mercadante S, Casuccio A, Mangione S. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage. 2007;33(2):217-23.PubMed
56.
Saif MW, Siddiqui IA, Sohail MA. Management of ascites due to gastrointestinal malignancy. Ann Saudi Med. 2009;29(5):369-77.PubMedPubMedCentral
57.
Sangisetty SL, Miner TJ. Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg. 2012;4(4):87-95.PubMedPubMedCentral
58.
Randle RW, Swett KR, Swords DS, et al. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol. 2014;21(5):1474-79.PubMed
59.
Ba MC, Cui SZ, Lin SQ, et al. Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol. 2010;16(15):1901-07.PubMedPubMedCentral
60.
Valle SJ, Alzahrani NA, Alzahrani SE, Liauw W, Morris DL. Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for refractory malignant ascites in patients unsuitable for cytoreductive surgery. Int J Surg. 2015;23(Pt A):176-180.PubMed
Metadata
Title
The Chicago Consensus on Peritoneal Surface Malignancies: Palliative Care Considerations
Author
Chicago Consensus Working Group
Publication date
01-06-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 6/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08323-x

Other articles of this Issue 6/2020

Annals of Surgical Oncology 6/2020 Go to the issue

Pancreatic Tumors

Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study

Translational Research and Biomarkers

Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer

Translational Research and Biomarkers

Combined Evaluation of Tumor-Infiltrating CD8 + and FoxP3 + Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma

Peritoneal Surface Malignancy

The Chicago Consensus on Peritoneal Surface Malignancies: Standards

ASO Author Reflections

ASO Author Reflections: SLNB with RT May Be Sufficient in Occult Breast Cancer after NAC

Health Services Research and Global Oncology

Cancer Surgery and COVID19